Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2025 | 347 | 4.770 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 6 | 2023 | 33 | 4.210 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 418 | 2.770 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2022 | 53 | 1.920 |
Why?
|
| SEER Program | 6 | 2025 | 74 | 1.190 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 507 | 1.180 |
Why?
|
| Multimorbidity | 3 | 2025 | 49 | 1.150 |
Why?
|
| Early Detection of Cancer | 6 | 2024 | 323 | 1.020 |
Why?
|
| Aged | 38 | 2025 | 14457 | 0.980 |
Why?
|
| Diet | 5 | 2021 | 527 | 0.890 |
Why?
|
| Electronic Health Records | 5 | 2023 | 367 | 0.850 |
Why?
|
| United States | 25 | 2025 | 7837 | 0.830 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 5468 | 0.830 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 71 | 0.760 |
Why?
|
| Paraproteinemias | 1 | 2022 | 16 | 0.740 |
Why?
|
| Middle Aged | 34 | 2025 | 17659 | 0.740 |
Why?
|
| Breast Neoplasms | 5 | 2025 | 1204 | 0.740 |
Why?
|
| Male | 40 | 2025 | 29937 | 0.720 |
Why?
|
| Prostate-Specific Antigen | 3 | 2022 | 77 | 0.720 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 277 | 0.710 |
Why?
|
| Humans | 60 | 2025 | 63533 | 0.710 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 135 | 0.660 |
Why?
|
| Cause of Death | 3 | 2020 | 221 | 0.650 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 363 | 0.640 |
Why?
|
| Case-Control Studies | 12 | 2022 | 1120 | 0.640 |
Why?
|
| Registries | 5 | 2025 | 873 | 0.610 |
Why?
|
| Adult | 26 | 2025 | 16895 | 0.590 |
Why?
|
| Disease Progression | 6 | 2023 | 1170 | 0.590 |
Why?
|
| Comorbidity | 6 | 2025 | 1115 | 0.560 |
Why?
|
| Algorithms | 2 | 2021 | 1005 | 0.550 |
Why?
|
| Hypertension | 1 | 2023 | 590 | 0.540 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 281 | 0.500 |
Why?
|
| Female | 26 | 2025 | 32945 | 0.480 |
Why?
|
| Fatty Acids | 2 | 2018 | 200 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 215 | 0.460 |
Why?
|
| Risk Factors | 14 | 2022 | 5284 | 0.460 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 54 | 0.450 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 784 | 0.420 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 19 | 0.410 |
Why?
|
| Population Health | 2 | 2023 | 17 | 0.390 |
Why?
|
| Dietary Fats | 2 | 2017 | 174 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 844 | 0.380 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2024 | 5 | 0.370 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 120 | 0.360 |
Why?
|
| Prospective Studies | 11 | 2020 | 3296 | 0.350 |
Why?
|
| Vitamin D | 1 | 2012 | 140 | 0.340 |
Why?
|
| Young Adult | 9 | 2025 | 4713 | 0.330 |
Why?
|
| Zinc | 1 | 2011 | 92 | 0.320 |
Why?
|
| Medicare | 2 | 2025 | 612 | 0.320 |
Why?
|
| Cytokines | 1 | 2013 | 934 | 0.310 |
Why?
|
| Sweden | 4 | 2017 | 57 | 0.310 |
Why?
|
| Tooth Loss | 2 | 2008 | 8 | 0.290 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 38 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2025 | 846 | 0.280 |
Why?
|
| Mammography | 2 | 2022 | 290 | 0.270 |
Why?
|
| Neoplasms | 4 | 2019 | 1373 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 491 | 0.260 |
Why?
|
| Mortality | 3 | 2019 | 161 | 0.260 |
Why?
|
| Mass Screening | 3 | 2024 | 692 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 2464 | 0.260 |
Why?
|
| Cohort Studies | 7 | 2017 | 2572 | 0.260 |
Why?
|
| Endoribonucleases | 2 | 2013 | 56 | 0.260 |
Why?
|
| Fruit | 2 | 2015 | 109 | 0.250 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 2704 | 0.250 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 518 | 0.250 |
Why?
|
| HIV Infections | 1 | 2013 | 972 | 0.250 |
Why?
|
| Puerto Rico | 3 | 2024 | 135 | 0.250 |
Why?
|
| Massachusetts | 4 | 2024 | 2074 | 0.240 |
Why?
|
| Health Services Research | 2 | 2017 | 270 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 448 | 0.230 |
Why?
|
| Biomarkers | 3 | 2022 | 1406 | 0.230 |
Why?
|
| Age Factors | 4 | 2021 | 1561 | 0.220 |
Why?
|
| Adolescent | 6 | 2024 | 6258 | 0.210 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2023 | 43 | 0.210 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 728 | 0.210 |
Why?
|
| Occult Blood | 1 | 2023 | 19 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 188 | 0.200 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2022 | 14 | 0.190 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 15 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 46 | 0.190 |
Why?
|
| Survival Rate | 3 | 2025 | 853 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 68 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2584 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 35 | 0.180 |
Why?
|
| Smoking | 3 | 2021 | 863 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 456 | 0.170 |
Why?
|
| Electronics | 1 | 2021 | 35 | 0.170 |
Why?
|
| Trans Fatty Acids | 1 | 2020 | 5 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 70 | 0.170 |
Why?
|
| Erythrocyte Membrane | 1 | 2020 | 24 | 0.170 |
Why?
|
| Precision Medicine | 2 | 2019 | 121 | 0.170 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 39 | 0.170 |
Why?
|
| Outpatients | 1 | 2022 | 138 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 61 | 0.170 |
Why?
|
| Pandemics | 2 | 2022 | 671 | 0.170 |
Why?
|
| Europe | 1 | 2021 | 197 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 130 | 0.170 |
Why?
|
| Social Class | 1 | 2021 | 136 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2021 | 65 | 0.160 |
Why?
|
| Antigens | 1 | 2021 | 147 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2012 | 584 | 0.160 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 166 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 13 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2010 | 185 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 435 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 70 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2020 | 308 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 762 | 0.150 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 18 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 229 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 391 | 0.150 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2018 | 17 | 0.150 |
Why?
|
| Prognosis | 3 | 2019 | 1744 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 485 | 0.140 |
Why?
|
| Periodontal Diseases | 1 | 2008 | 17 | 0.140 |
Why?
|
| Periodontitis | 1 | 2008 | 15 | 0.140 |
Why?
|
| Incidence | 5 | 2025 | 1374 | 0.140 |
Why?
|
| Sex Factors | 1 | 2021 | 973 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 150 | 0.140 |
Why?
|
| Telemedicine | 1 | 2022 | 330 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 167 | 0.130 |
Why?
|
| Organizational Objectives | 1 | 2017 | 58 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2018 | 760 | 0.130 |
Why?
|
| Dairy Products | 1 | 2017 | 16 | 0.130 |
Why?
|
| Lymphoma | 1 | 2017 | 104 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2019 | 120 | 0.130 |
Why?
|
| Education | 1 | 2017 | 68 | 0.130 |
Why?
|
| Milk | 1 | 2017 | 44 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2017 | 67 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1092 | 0.130 |
Why?
|
| Health Personnel | 2 | 2013 | 377 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 259 | 0.130 |
Why?
|
| Cholesterol | 1 | 2017 | 259 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 2018 | 161 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 509 | 0.120 |
Why?
|
| Inflammation | 2 | 2021 | 1146 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 14 | 0.120 |
Why?
|
| Genomics | 1 | 2018 | 375 | 0.120 |
Why?
|
| Connecticut | 1 | 2015 | 87 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2016 | 208 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 73 | 0.110 |
Why?
|
| Meat | 1 | 2015 | 34 | 0.110 |
Why?
|
| Vegetables | 1 | 2015 | 69 | 0.110 |
Why?
|
| Vasectomy | 1 | 2014 | 1 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 662 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 196 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1105 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 313 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2013 | 38 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 262 | 0.100 |
Why?
|
| Veterans | 1 | 2021 | 763 | 0.100 |
Why?
|
| Time Factors | 3 | 2012 | 3710 | 0.100 |
Why?
|
| Prevalence | 1 | 2017 | 1386 | 0.100 |
Why?
|
| Obesity | 1 | 2021 | 1234 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 8 | 0.100 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 11 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 120 | 0.090 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 34 | 0.090 |
Why?
|
| Nursing Homes | 1 | 2018 | 671 | 0.090 |
Why?
|
| Health Behavior | 1 | 2015 | 472 | 0.090 |
Why?
|
| Seasons | 1 | 2012 | 135 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 252 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 868 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 344 | 0.080 |
Why?
|
| Genotype | 3 | 2013 | 664 | 0.080 |
Why?
|
| California | 2 | 2020 | 174 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 769 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 719 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2022 | 498 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 35 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 2027 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1535 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2013 | 320 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 1267 | 0.060 |
Why?
|
| Vietnam | 1 | 2025 | 173 | 0.060 |
Why?
|
| Trust | 1 | 2024 | 77 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 134 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6620 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 230 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 114 | 0.040 |
Why?
|
| Life Tables | 1 | 2020 | 23 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 156 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 45 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2010 | 5 | 0.040 |
Why?
|
| Finland | 1 | 2010 | 20 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 43 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 384 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 7 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 75 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 89 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5630 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 112 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 364 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 28 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 313 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 33 | 0.040 |
Why?
|
| Colorado | 1 | 2019 | 21 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 26 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 498 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 91 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 375 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 369 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 381 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 150 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 204 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 536 | 0.040 |
Why?
|
| Research | 1 | 2019 | 195 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2020 | 303 | 0.030 |
Why?
|
| Data Collection | 1 | 2019 | 384 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 232 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 312 | 0.030 |
Why?
|
| Research Personnel | 1 | 2017 | 94 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1259 | 0.030 |
Why?
|
| Mentors | 1 | 2017 | 121 | 0.030 |
Why?
|
| Kenya | 1 | 2016 | 92 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 29 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 443 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 575 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 172 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 417 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 277 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 447 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 897 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 378 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 25 | 0.020 |
Why?
|
| Prostate | 1 | 2013 | 90 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2013 | 99 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 628 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 867 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 32 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 47 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1654 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1999 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4541 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 20715 | 0.010 |
Why?
|